Polar Capital’s Puma Biotechnology PBYI Stock Holding History

Polar Capital’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-445,000	Closed	-$44M	–	272
2017 Q4	$44M	Buy	445,000 +85,000	+24%	+$9.51M	0.45%	63
2017 Q3	$43.1M	Buy	+360,000	New	+$33.5M	0.49%	62
2014 Q2	–	Sell	-142,152	Closed	-$14.8M	–	278
2014 Q1	$14.8M	Buy	142,152 +8,642	+6%	+$1.02M	0.34%	110
2013 Q4	$13.8M	Sell	133,510 -46,510	-26%	-$2.73M	0.33%	118
2013 Q3	$9.66K	Buy	180,020 +30,020	+20%	+$1.62M	0.26%	144
2013 Q2	$6.66M	Buy	+150,000	New	+$5.29M	0.23%	158

Other funds holding PBYI

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Polar Capital's PBYI Position: Q1 2018 in Review

Polar Capital sold out of Puma Biotechnology (PBYI) in Q1 2018, closing a stake of 445,000 shares — an estimated $44M sold.

Polar Capital first reported a position in PBYI in Q2 2013 and held it in 6 quarters. The position peaked at $44M in Q4 2017. 178 funds tracked by Wall St. Rank hold PBYI as of Q1 2018.

Polar Capital reported no remaining Puma Biotechnology position as of Q1 2018 after selling out during the quarter.
Polar Capital sold 445,000 Puma Biotechnology shares in Q1 2018, an estimated $44M.
Polar Capital first reported a position in Puma Biotechnology in Q2 2013 and held it in 6 quarters.
Polar Capital's Puma Biotechnology position peaked at $44M in Q4 2017.
178 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2018.

Based on Polar Capital's 13F filing for Q1 2018, filed 15 May 2018.